Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) EBIT Margin (2020 - 2024)

Goldenwell Biotech's EBIT Margin history spans 5 years, with the latest figure at 45674.05% for Q4 2024.

  • For Q4 2024, EBIT Margin fell 3767444.0% year-over-year to 45674.05%; the TTM value through Sep 2025 reached 35406.33%, down 1131961.0%, while the annual FY2024 figure was 19853.96%, 1851158.0% down from the prior year.
  • EBIT Margin reached 45674.05% in Q4 2024 per GWLL's latest filing, down from 34402.88% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 2261.3% in Q2 2021 to a low of 45674.05% in Q4 2024.
  • Average EBIT Margin over 5 years is 9245.0%, with a median of 2920.0% recorded in 2020.
  • Peak YoY movement for EBIT Margin: skyrocketed 604653bps in 2023, then tumbled -3767444bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 2920.0% in 2020, then skyrocketed by 95bps to 133.52% in 2021, then soared by 92bps to 10.49% in 2022, then tumbled by -76144bps to 7999.62% in 2023, then crashed by -471bps to 45674.05% in 2024.
  • Per Business Quant, the three most recent readings for GWLL's EBIT Margin are 45674.05% (Q4 2024), 34402.88% (Q2 2024), and 7999.62% (Q4 2023).